Experimental Becker dystrophy drug shows stable function over 3.5 years Long-term MESA data show sevasemten patients maintained NSAA scores versus predicted Becker decline in natural history. GRAND CANYON readout 4Q 2026.

#EWTX Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

www.stocktitan.net/news/EWTX/edgewise-annou...

Edgewise Therapeutics Announces Inducement Stock Option Grants for New Employees Edgewise Therapeutics has granted stock options to new employees, as part of their strategy to attract talent and comply with Nasdaq listing rules.

Edgewise Therapeutics Announces Inducement Stock Option Grants for New Employees #United_States #biopharmaceuticals #Boulder #Edgewise_Therapeutics #EWTX

Edgewise Therapeutics Unveils Financial Progress and Upcoming Milestones for 2025 and Beyond Edgewise Therapeutics has revealed its financial results for 2025, showcasing strong advancements in muscular dystrophy and cardiovascular programs.

Edgewise Therapeutics Unveils Financial Progress and Upcoming Milestones for 2025 and Beyond #USA #Boulder #Edgewise_Therapeutics #Sevasemten #EWTX

Heart failure and muscular dystrophy drugs from Edgewise face 2026 tests Cash reserves of $530.1M fund Edgewise’s Duchenne, Becker and HCM studies as Q4 2025 net loss widens to $50.2M; multiple 2026 readouts loom.

#EWTX Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

www.stocktitan.net/news/EWTX/edgewise-thera...

Edgewise Therapeutics Announces Inducement Grants to Enhance Workforce Engagement and Growth Edgewise Therapeutics, a leader in muscle disease biopharma, reveals its recent inducement stock options to attract new talents and foster innovation.

Edgewise Therapeutics Announces Inducement Grants to Enhance Workforce Engagement and Growth #United_States #Boulder #Edgewise_Therapeutics #Muscle_Disease #EWTX

New muscular dystrophy and heart drug trials target key 2026 results Edgewise maps 2026 goals, from pivotal Becker data and Phase 3 HCM trial start to EDG-15400 heart failure study and a $200M cash boost.

#EWTX Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

www.stocktitan.net/news/EWTX/edgewise-thera...

Edgewise Therapeutics to Showcase at 44th J.P. Morgan Healthcare Conference in January 2026 Edgewise Therapeutics is set to present at the prestigious J.P. Morgan Healthcare Conference, detailing advancements in muscle disease therapies and clinical trials.

Edgewise Therapeutics to Showcase at 44th J.P. Morgan Healthcare Conference in January 2026 #USA #Boulder #Edgewise_Therapeutics #EWTX #Kevin_Koch

Edgewise Therapeutics Grants Inducement Stock Options to New Employees Edgewise Therapeutics recently granted stock options to new hires as part of its efforts to attract talent, adhering to Nasdaq Listing Rules.

Edgewise Therapeutics Grants Inducement Stock Options to New Employees #United_States #Boulder #Edgewise_Therapeutics #Muscle_Disease #EWTX

Just In: ( NASDAQ: #EWTX ) Why Edgewise Therapeutics Stock Rocked the Market Today

BREAKING NEWS: ( NASDAQ: #EWTX ) Buy Recommendation Issued On EWTX By H.C. Wainwright

Leading Indicators, Tuesday November 11, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Nov 11th - #STAA #ORMP #ADSE #BCIC #CECO #DSGN #EWTX #GANX #HCAI #INNV #PUBM #NTHI #YEXT #VAN #SFL #NVRI #KOP #FIGS #DV #BAK - More: crystalequityresearch.com/leading-indi... - #smallcap

Edgewise Therapeutics Announces Participation in Noteworthy Investor Conferences Edgewise Therapeutics, a biopharmaceutical leader, will be featured in prominent investor conferences showcasing innovative therapies for muscle diseases.

Edgewise Therapeutics Announces Participation in Noteworthy Investor Conferences #United_States #Boulder #muscle_diseases #Edgewise_Therapeutics #EWTX

#EWTX Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/EWTX/edgewise-thera...

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics for Possible Securities Fraud Pomerantz LLP is currently investigating potential claims involving Edgewise Therapeutics, Inc. amid concerns of securities fraud. Shareholders can participate.

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics for Possible Securities Fraud #United_States #New_York #Pomerantz_LLP #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics Investors' Claims Pomerantz LLP is probing claims from Edgewise Therapeutics investors following potential securities fraud. Reach out for details.

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics Investors' Claims #None #Pomerantz_LLP #Edgewise_Therapeutics #EWTX

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights –Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies–. BOULDER, Colo., Aug. 7, 2025/ PRNewswire/-- Edgewise Therapeutics, Inc.,, a leading muscle disease biopharmaceutical company, today reported financial results for the second...

#EWTX Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/EWTX/edgewise-thera...

Edgewise Therapeutics Announces New Inducement Stock Options for Employees under Nasdaq Listing Rules Edgewise Therapeutics, a leader in muscle disease therapies, has announced the granting of inducement stock options to new employees, enhancing its workforce under Nasdaq rules.

Edgewise Therapeutics Announces New Inducement Stock Options for Employees under Nasdaq Listing Rules #USA #Boulder #Edgewise_Therapeutics #Muscle_Disease #EWTX

Pomerantz Law Firm Investigates Potential Securities Fraud Involving Edgewise Therapeutics, Inc. Pomerantz LLP is investigating possible securities fraud involving Edgewise Therapeutics, Inc., after recent clinical trial results. Investors urged to contact the firm.

Pomerantz Law Firm Investigates Potential Securities Fraud Involving Edgewise Therapeutics, Inc. #United_States #New_York #Pomerantz_Law_Firm #Edgewise_Therapeutics #EWTX

Leading Indicators, Wednesday July 30, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator, Wed Jul 30th - #XTKG #VYGR #SENEA #RCKY #NWPX #LAB #FAT #EWTX #BRY #ATXS #TNK #NAT #LXFR #GCI #BRSP #ASC - More: crystalequityresearch.com/leading-indi... - #smallcap

Investigation Launched by Pomerantz Law Firm for Edgewise Therapeutics Investors Pomerantz LLP is probing potential securities fraud claims on behalf of investors in Edgewise Therapeutics, Inc. following unsettling clinical trial results.

Investigation Launched by Pomerantz Law Firm for Edgewise Therapeutics Investors #United_States #New_York #Pomerantz_Law_Firm #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Investigates Edgewise Therapeutics for Potential Securities Fraud Claims Pomerantz Law Firm is probing potential securities fraud claims against Edgewise Therapeutics, following troubling data on their clinical trials. Investors should take note.

Pomerantz Law Firm Investigates Edgewise Therapeutics for Potential Securities Fraud Claims #United_States #New_York #Pomerantz_Law #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics, Inc. for Possible Securities Fraud Pomerantz LLP investigates Edgewise Therapeutics, Inc. for potential securities fraud linked to its recent clinical trial data.

Pomerantz Law Firm Launches Investigation into Edgewise Therapeutics, Inc. for Possible Securities Fraud #United_States #New_York #Pomerantz_LLP #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics Pomerantz LLP is looking into claims of possible securities fraud involving Edgewise Therapeutics, following recent critical FDA communications impacting stock value.

Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics #USA #New_York #Pomerantz_LLP #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Probes Edgewise Therapeutics for Investor Claims Amid SEC Violations Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, focusing on potential securities fraud and business misconduct.

Pomerantz Law Firm Probes Edgewise Therapeutics for Investor Claims Amid SEC Violations #New_York #Pomerantz_LLP #Edgewise_Therapeutics #EWTX

Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics, Inc. Pomerantz LLP is looking into claims related to Edgewise Therapeutics, following their stock decline after clinical trial results. Investors are advised to engage.

Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics, Inc. #USA #New_York #Pomerantz_Law #Edgewise_Therapeutics #EWTX

Breakthrough: First-Ever Becker Muscular Dystrophy Treatment Shows 3-Year Disease Stabilization New clinical data reveals sustained efficacy for novel muscular dystrophy drug sevasemten. FDA pathway confirmed for first-ever Becker treatment. See detailed trial results.

#EWTX Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

www.stocktitan.net/news/EWTX/edgewise-thera...

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Edgewise Therapeutics (NASDAQ: EWTX) reported Q1 2025 financial results and business updates. The company announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy. They strengthened their financial position through a $200M public offering, resulting in pro-forma cash balance exceeding $624M. Key developments include: completed enrollment in GRAND CANYON trial for Becker muscular dystrophy with 175 adults; positive data from CANYON trial; and advancing CIRRUS-HCM trial showing promising results. Q1 2025 financials showed R&D expenses of $36.8M and net loss of $40.8M ($0.43 per share). The company expects to report data from Phase 2 LYNX and FOX trials in Duchenne muscular dystrophy in Q2 2025 and Part D of CIRRUS-HCM trial in H2 2025.

#EWTX Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/EWTX/edgewise-thera...

www.fool.com/investing/2025/05/02/why...

#EWTX […]

[Original post on fool.com]